Last reviewed · How we verify
Bevacizumab control
Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis and reduce blood supply to cancer cells.
Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis and reduce blood supply to cancer cells. Used for Metastatic colorectal cancer (in combination with chemotherapy), Metastatic non-small cell lung cancer (in combination with chemotherapy), Metastatic breast cancer (in combination with chemotherapy).
At a glance
| Generic name | Bevacizumab control |
|---|---|
| Sponsor | Institut de Recherches Internationales Servier |
| Drug class | VEGF inhibitor (monoclonal antibody) |
| Target | VEGF (Vascular Endothelial Growth Factor) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bevacizumab binds to circulating VEGF, preventing its interaction with VEGF receptors on endothelial cells. This inhibits the formation of new blood vessels that tumors require for growth and metastasis. By starving tumors of their blood supply, bevacizumab slows tumor progression and is typically used in combination with chemotherapy or other targeted agents.
Approved indications
- Metastatic colorectal cancer (in combination with chemotherapy)
- Metastatic non-small cell lung cancer (in combination with chemotherapy)
- Metastatic breast cancer (in combination with chemotherapy)
- Glioblastoma (recurrent)
- Metastatic renal cell carcinoma (in combination with interferon-alpha)
Common side effects
- Hypertension
- Proteinuria
- Bleeding/hemorrhage
- Thromboembolic events
- Gastrointestinal perforation
- Wound healing complications
- Fatigue
Key clinical trials
- Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (PHASE3)
- Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer (PHASE3)
- A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. (PHASE2, PHASE3)
- SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety (PHASE2)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment (PHASE2)
- Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases (PHASE3)
- Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Procedure Time, Patient Satisfaction, and Safety (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |